A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)
Phase 3
Completed
NCT05084053
| Condition | Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Multifocal Motor Neuropathy |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Takeda |
|---|
| Status | Completed |
|---|
| Enrollment | 26 participants |
|---|
| Interventions | TAK-771 |
|---|
| Start date | Jan 19, 2022 |
|---|
| Completion date | Oct 28, 2025 |
|---|
| Results posted | Mar 18, 2025 |
|---|
Summary
The main aim of the study is to check for side effects from TAK-771, and to check how well TAK-771 controls symptoms in Japanese participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) The participants will be treated with TAK-771 for 45 months as a maximum. There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug (every 2, 3, or 4 weeks).
Epoch 1: Percentage of Participants With CIDP Who Experienced Relapse
Epoch 1: Baseline up to 6 months · percentage of participants
| Epoch 1, Cohort 1 (CIDP): TAK-771 | 0 percentage of participants |
|---|
Epoch 1: Change From Baseline in Maximum Grip Strength in the More Affected Hand in Participants With MMN
Epoch 1: Baseline up to 6 months · kPa
| Epoch 1, Cohort 2 (MMN): TAK-771 | -1.1 ± 12.73 kPa |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.